UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2014
REVANCE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| DELAWARE | 001-36297 | 75-0551645 | ||
| (State of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
Revance Therapeutics, Inc.
7555 Gateway Boulevard
Newark, California 94560
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (510) 742-3400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 8.01 OTHER EVENTS.
On October 30, 2014, Revance Therapeutics, Inc. (the “Company”) submitted a comment letter to the U.S. Food and Drug Administration (the “FDA”) regarding the FDA’s Draft Guidance for Industry, Upper Facial Lines: Developing Botulinum Toxin Drug Products (Docket No. 2014-D-0968), published in the Federal Register on August 6, 2014.
The text of the comment letter is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
| Number |
Description | |
| 99.1 | Comment Letter on FDA’s Draft Guidance | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 3, 2014 | Revance Therapeutics, Inc. | |||
| By: |
/s/ Lauren P. Silvernail | |||
| Lauren P. Silvernail | ||||
| Executive Vice President, Corporate Development and Chief Financial Officer | ||||
EXHIBIT INDEX
| Number |
Description | |
| 99.1 | Comment Letter on FDA’s Draft Guidance | |